Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions:

• The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements.
• Based on current planning, the Company expects a net loss of approximately EUR 23.5 million for the 2025 financial year.

This forecast reflects expected research and development expenses of around EUR 11 million and personnel and other operating expenses of around EUR 9.5 million. Potential revenues from out-licensing activities are not included in the forecast.

The full Annual Report for the 2024 financial year was published today, on April 15, 2025. The Company will host an investor call to present the financial results at 2:00 p.m. CEST on the same day. Registration is available at the following link:

Link to registration

About Pentixapharm

Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases.

For more information, please contact:

Pentixapharm Holding AG
Phillip Eckert, Investor Relations
ir@pentixapharm.com
Tel. +49 30 94893232
www.pentixapharm.com